{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:29:12Z","timestamp":1756384152157,"version":"3.37.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FIS\/Fondos FEDER","award":["PI17\/00257","PI18\/01386","PI19\/00588","PI19\/00815","DTS18\/00032","ERA-PerMed-JTC2018"],"award-info":[{"award-number":["PI17\/00257","PI18\/01386","PI19\/00588","PI19\/00815","DTS18\/00032","ERA-PerMed-JTC2018"]}]},{"name":"KIDNEY ATTACK","award":["AC18\/00064"],"award-info":[{"award-number":["AC18\/00064"]}]},{"name":"PERSTIGAN","award":["AC18\/00071"],"award-info":[{"award-number":["AC18\/00071"]}]},{"name":"ISCIII-RETIC REDinREN","award":["RD016\/0009"],"award-info":[{"award-number":["RD016\/0009"]}]},{"name":"Sociedad Espa\u00f1ola de Nefrolog\u00eda, FRIAT"},{"name":"Comunidad de Madrid en Biomedicina","award":["B2017\/BMD-3686 CIFRA2-CM"],"award-info":[{"award-number":["B2017\/BMD-3686 CIFRA2-CM"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nephrologists are familiar with severe cases of anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) presenting as rapidly progressive glomerulonephritis. However, less is known about AAV with slowly progressive renal involvement. While its existence is acknowledged in textbooks, much remains unknown regarding its relative frequency versus more aggressive cases as well as about the optimal therapeutic approach and response to therapy. Moreover, this uncommon presentation may be underdiagnosed, given the scarce familiarity of physicians. In this issue of Clinical Kidney Journal, Trivioli et al. report the largest series to date and first systematic assessment of patients with AAV and slowly progressive renal involvement, defined as a reduction in estimated glomerular filtration rate (eGFR) of 25\u201350% in the 6\u2009months prior to diagnosis after excluding secondary causes. Key findings are that slowly progressive AAV may be less common than previously thought, although it still represents the second most common presentation of renal AAV, it usually has a microscopic polyangiitis, anti-myeloperoxidase, mainly renal phenotype in elderly individuals, diagnosis may be late (over one-third of patients had end-stage kidney disease at diagnosis), clearly identifying an unmet need for physician awareness about this presentation, but those not needing renal replacement therapy at diagnosis still responded to immunosuppression.<\/jats:p>","DOI":"10.1093\/ckj\/sfaa181","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T19:54:29Z","timestamp":1597089269000},"page":"18-22","source":"Crossref","is-referenced-by-count":1,"title":["Slo-Mo anti-neutrophil cytoplasmic antibody-associated renal vasculitis"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-0588","authenticated-orcid":false,"given":"Alejandro","family":"Avello","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, IIS-Fundaci\u00f3n Jim\u00e9nez Diaz, Division of Nephrology and Hypertension, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos III-FEDER, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-1137","authenticated-orcid":false,"given":"Raul","family":"Fernandez-Prado","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, IIS-Fundaci\u00f3n Jim\u00e9nez Diaz, Division of Nephrology and Hypertension, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos III-FEDER, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Santos-Sanchez-Rey","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, IIS-Fundaci\u00f3n Jim\u00e9nez Diaz, Division of Nephrology and Hypertension, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos III-FEDER, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Rojas-Rivera","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, IIS-Fundaci\u00f3n Jim\u00e9nez Diaz, Division of Nephrology and Hypertension, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos III-FEDER, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, IIS-Fundaci\u00f3n Jim\u00e9nez Diaz, Division of Nephrology and Hypertension, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos III-FEDER, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"2021020321160490900_sfaa181-B1","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaa139","article-title":"Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis. Clinico-pathological characterization and outcome","author":"Trivioli","year":"2021","journal-title":"Clin Kidney J"},{"key":"2021020321160490900_sfaa181-B2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2169\/internalmedicine.41.418","article-title":"Slowly progressive, not rapidly progressive, MPO-ANCA positive glomerulonephritis and its characteristics","volume":"41","author":"Nakabayashi","year":"2002","journal-title":"Intern Med"},{"key":"2021020321160490900_sfaa181-B3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2169\/internalmedicine.41.458","article-title":"MPO-ANCA-positive slowly progressive glomerulonephritis with focal tuft necrosis and crescents","volume":"41","author":"Aoyama","year":"2002","journal-title":"Intern Med"},{"key":"2021020321160490900_sfaa181-B4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1744-9987.12249","article-title":"Juvenile slow progressive antineutrophil cytoplasmic antibody-associated vasculitis diagnosed after kidney transplantation: a case report","volume":"19","author":"Hasegawa","year":"2015","journal-title":"Ther Apher Dial"},{"key":"2021020321160490900_sfaa181-B5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2169\/internalmedicine.38.679","article-title":"Atypical Wegener\u2019s granulomatosis with positive cytoplasmic antineutrophil cytoplasmic antibodies, ophthalmologic manifestations, and slowly progressive renal failure without respiratory tract involvement","volume":"38","author":"Kakizawa","year":"1999","journal-title":"Intern Med"},{"key":"2021020321160490900_sfaa181-B6","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"ANCA Glomerulonephritis and Vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321160490900_sfaa181-B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/kisup.2012.26","article-title":"Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021020321160490900_sfaa181-B8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021020321160490900_sfaa181-B9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.06010809","article-title":"Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2013a prospective, open-label pilot trial","volume":"5","author":"Silva","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321160490900_sfaa181-B10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021020321160490900_sfaa181-B11","doi-asserted-by":"crossref","first-page":"i132","DOI":"10.1093\/ndt\/gfv061","article-title":"Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital","volume":"30","author":"Draibe","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2021020321160490900_sfaa181-B12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321160490900_sfaa181-B13","doi-asserted-by":"crossref","DOI":"10.1007\/s00393-020-00803-5","article-title":"Comparative efficacy and safety of mycophenolate mofetil versus cyclophosphamide in patients with active antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of randomized trials","author":"Song","year":"2020","journal-title":"Z Rheumatol"},{"key":"2021020321160490900_sfaa181-B14","doi-asserted-by":"crossref","first-page":"e001195","DOI":"10.1136\/rmdopen-2020-001195","article-title":"Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis","volume":"6","author":"Kuzuya","year":"2020","journal-title":"RMD Open"},{"key":"2021020321160490900_sfaa181-B15","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"2021020321160490900_sfaa181-B16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2021020321160490900_sfaa181-B17","first-page":"386","article-title":"French Vasculitis Study Group, MAINRITSAN investigators. Rituximab or azathioprine maintenance in ANCA-associated vasculitis","volume":"372","author":"Pagnoux","year":"2015","journal-title":"N Engl J Med"},{"key":"2021020321160490900_sfaa181-B18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021020321160490900_sfaa181-B19","first-page":"137","article-title":"Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37(Suppl 117","author":"Montante","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2021020321160490900_sfaa181-B20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021020321160490900_sfaa181-B21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2021020321160490900_sfaa181-B22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"2021020321160490900_sfaa181-B23","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2021020321160490900_sfaa181-B24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/1\/18\/36184787\/sfaa181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/1\/18\/36184787\/sfaa181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T10:07:02Z","timestamp":1612778822000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/1\/18\/5964143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,9]]},"published-print":{"date-parts":[[2021,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa181","relation":{},"ISSN":["2048-8513"],"issn-type":[{"type":"electronic","value":"2048-8513"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,11,9]]}}}